Auxilium Pharmaceuticals (AUXL) 25.97 $AUXL
Shares of AUXL Down 11.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 14, 9:20AM CDT
SmarTrend identified a Downtrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on March 25th, 2014 at $28.52. In approximately 3 weeks, Auxilium Pharmaceuticals has returned 11.91% as of today's recent price of $25.12.
Auxilium and Sobi announce encore presentation of Xiapex data at European Association of urology congress
Thomson Reuters ONE - Mon Apr 14, 5:06AM CDT
- Encore data highlighted from trials evaluating Xiaflex/Xiapex, the first and only FDA approved treatment for Peyronie's Disease.
Auxilium and Sobi Announce Encore Presentation of XIAFLEX/Xiapex Data at European Association of Urology Congress
PR Newswire - Mon Apr 14, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX®/ Xiapex® (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These data were presented at the 29th Annual European Association of Urology (EAU) Congress being held April 11 - 15, 2014 in Stockholm, Sweden.
Certifications, Authorizations, Stock Updates, and Upcoming Conferences - Analyst Notes on Edwards Lifesciences, Alkermes, ResMed, Auxilium, and Teleflex
PR Newswire - Thu Apr 10, 11:23AM CDT
Today, Analysts Review released its analysts' notes regarding Edwards Lifesciences Corp (NYSE: EW), Alkermes Plc (NASDAQ: ALKS), ResMed Inc. (NYSE: RMD), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), and Teleflex Incorporated (NYSE: TFX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Sobi announced as Market Authorisation Holder for Xiapex in 28 EU member countries, Norway and Iceland
M2 - Mon Apr 07, 9:38AM CDT
Biopharmaceutical company Auxilium Pharmaceuticals (NasdaqGS:AUXL) stated on Monday that Swedish Orphan Biovitrum AB (publ) (Sobi) became the Market Authorisation Holder (MAH) for the former's Xiapex (collagenase clostridium histolyticum) in 28 EU member countries, Norway and Iceland on 3 April 2014.
Sobi Becomes Market Authorisation Holder For Xiapex in Europe
PR Newswire - Mon Apr 07, 5:00AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014.
Sobi becomes market authorisation holder for Xiapex in Europe
Thomson Reuters ONE - Mon Apr 07, 1:02AM CDT
Stockholm, Sweden and Chesterbrook, Pa., 7 April, 2014 -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex(R) (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on 3 April, 2014.
Biotech Auxilium Boosts Position In Men's Health Care
at Investor's Business Daily - Tue Apr 01, 4:31PM CDT
It takes some doing for a small fry to take on Big Pharma. But that's part of the game plan for Adrian Adams, CEO of men's health care-focused specialty biotech Auxilium Pharmaceuticals (AUXL). Adams took Auxilium's helm in December 2011. At the time...
First Week of May 17th Options Trading For Auxilium Pharmaceuticals (AUXL)
DividendChannel.com - Thu Mar 27, 10:16AM CDT
Investors in Auxilium Pharmaceuticals Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AUXL options chain for the new May 17th contracts and...
Auxilium Pharmaceuticals Shares Up 47.7% Since SmarTrend's Buy Recommendation (AUXL)
Comtex SmarTrend(R) - Fri Mar 21, 9:13AM CDT
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on December 6th, 2013 at $20.67. In approximately 4 months, Auxilium Pharmaceuticals has returned 47.74% as of today's recent price of $30.53.
Apricus Biosciences Expands Senior Management Team, Appointing Neil C. Morton as Vice President, Business Development
GlobeNewswire - Thu Mar 20, 7:00AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced the appointment of Neil C. Morton as Vice President of Business Development. Mr. Morton brings to Apricus a successful track record in business development in specialty pharmaceuticals, most recently serving as the Executive Director of Business Development at Auxilium Pharmaceuticals Inc., where he successfully led their efforts to build a pipeline of men's health products to include in-licensing of Stendra(TM) from Vivus, Inc. and the acquisition of Actient Pharmaceuticals. He will report to Richard Pascoe, Apricus' Chief Executive Officer, and his appointment is effective immediately. Edward Cox, who previously served in this position, will transition to the newly created role of Vice President of Commercial Development where he will primarily focus on supporting the launch of Vitaros in Europe and Canada.
Earnings Look Back: Auxilium Pharmaceuticals Is Down 3.7% Since Reporting Quarterly Results 2 Weeks Ago (AUXL)
Comtex SmarTrend(R) - Mon Mar 17, 7:03AM CDT
Two weeks ago on February 28th, 2014 Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings and analysts, on average, expected earnings of $0.21 on sales of $112.0 million. Auxilium Pharmaceuticals actually reported earnings of $0.27 per share on sales of $125.9 million, beating EPS estimates by $0.06 and beating revenue estimates by $13.9 million. Since the company's report, shares of Auxilium Pharmaceuticals have fallen from $30.75 to $29.61, representing a loss of 3.7% in the past 17 days.
Auxilium Pharmaceuticals Has Returned 41.4% Since SmarTrend Recommendation (AUXL)
Comtex SmarTrend(R) - Thu Mar 13, 4:48PM CDT
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on December 6th, 2013 at $20.67. In approximately 3 months, Auxilium Pharmaceuticals has returned 41.35% as of today's recent price of $29.21.
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Update on Endo's Product Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 11:00AM CDT
The approval of Aveed has boosted Endo's top line.
Auxilium Pharmaceuticals Earnings Hindsight: Down 2.0% in Last 10 Days (AUXL)
Comtex SmarTrend(R) - Mon Mar 10, 7:42AM CDT
When Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings a week ago on February 28th, 2014, analysts, on average, expected the company to report earnings of $0.21 on sales of $112.0 million. Auxilium Pharmaceuticals actually reported earnings of $0.27 per share on sales of $125.9 million, beating EPS estimates by $0.06 and beating revenue estimates by $13.9 million. Since the company's report, shares of Auxilium Pharmaceuticals have fallen from $30.75 to $30.14, representing a loss of 2.0% in the past 10 days.
Setback for Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 2:55PM CST
Roche recently suffered a setback when it announced that an independent data monitoring committee has recommended that its phase III study, METLung, on onartuzumab (MetMab) should be stopped.
QLT Narrows Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 9:00AM CST
The narrower loss was due to the lower costs incurred by QLT in the final quarter of 2013.
Can Auxilium Pharma (AUXL) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:30AM CST
Auxilium Pharma has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy.
Shares of AUXL Down 11.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 14, 9:20AM CDT
SmarTrend identified a Downtrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on March 25th, 2014 at $28.52. In approximately 3 weeks, Auxilium Pharmaceuticals has returned 11.91% as of today's recent price of $25.12.
Auxilium and Sobi announce encore presentation of Xiapex data at European Association of urology congress
Thomson Reuters ONE - Mon Apr 14, 5:06AM CDT
- Encore data highlighted from trials evaluating Xiaflex/Xiapex, the first and only FDA approved treatment for Peyronie's Disease.
Auxilium and Sobi Announce Encore Presentation of XIAFLEX/Xiapex Data at European Association of Urology Congress
PR Newswire - Mon Apr 14, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX®/ Xiapex® (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These data were presented at the 29th Annual European Association of Urology (EAU) Congress being held April 11 - 15, 2014 in Stockholm, Sweden.
Certifications, Authorizations, Stock Updates, and Upcoming Conferences - Analyst Notes on Edwards Lifesciences, Alkermes, ResMed, Auxilium, and Teleflex
PR Newswire - Thu Apr 10, 11:23AM CDT
Today, Analysts Review released its analysts' notes regarding Edwards Lifesciences Corp (NYSE: EW), Alkermes Plc (NASDAQ: ALKS), ResMed Inc. (NYSE: RMD), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), and Teleflex Incorporated (NYSE: TFX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Sobi announced as Market Authorisation Holder for Xiapex in 28 EU member countries, Norway and Iceland
M2 - Mon Apr 07, 9:38AM CDT
Biopharmaceutical company Auxilium Pharmaceuticals (NasdaqGS:AUXL) stated on Monday that Swedish Orphan Biovitrum AB (publ) (Sobi) became the Market Authorisation Holder (MAH) for the former's Xiapex (collagenase clostridium histolyticum) in 28 EU member countries, Norway and Iceland on 3 April 2014.
Sobi Becomes Market Authorisation Holder For Xiapex in Europe
PR Newswire - Mon Apr 07, 5:00AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014.
Sobi becomes market authorisation holder for Xiapex in Europe
Thomson Reuters ONE - Mon Apr 07, 1:02AM CDT
Stockholm, Sweden and Chesterbrook, Pa., 7 April, 2014 -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex(R) (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on 3 April, 2014.
Biotech Auxilium Boosts Position In Men's Health Care
at Investor's Business Daily - Tue Apr 01, 4:31PM CDT
It takes some doing for a small fry to take on Big Pharma. But that's part of the game plan for Adrian Adams, CEO of men's health care-focused specialty biotech Auxilium Pharmaceuticals (AUXL). Adams took Auxilium's helm in December 2011. At the time...
First Week of May 17th Options Trading For Auxilium Pharmaceuticals (AUXL)
DividendChannel.com - Thu Mar 27, 10:16AM CDT
Investors in Auxilium Pharmaceuticals Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AUXL options chain for the new May 17th contracts and...
Auxilium Pharmaceuticals Shares Up 47.7% Since SmarTrend's Buy Recommendation (AUXL)
Comtex SmarTrend(R) - Fri Mar 21, 9:13AM CDT
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on December 6th, 2013 at $20.67. In approximately 4 months, Auxilium Pharmaceuticals has returned 47.74% as of today's recent price of $30.53.
Apricus Biosciences Expands Senior Management Team, Appointing Neil C. Morton as Vice President, Business Development
GlobeNewswire - Thu Mar 20, 7:00AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced the appointment of Neil C. Morton as Vice President of Business Development. Mr. Morton brings to Apricus a successful track record in business development in specialty pharmaceuticals, most recently serving as the Executive Director of Business Development at Auxilium Pharmaceuticals Inc., where he successfully led their efforts to build a pipeline of men's health products to include in-licensing of Stendra(TM) from Vivus, Inc. and the acquisition of Actient Pharmaceuticals. He will report to Richard Pascoe, Apricus' Chief Executive Officer, and his appointment is effective immediately. Edward Cox, who previously served in this position, will transition to the newly created role of Vice President of Commercial Development where he will primarily focus on supporting the launch of Vitaros in Europe and Canada.
Earnings Look Back: Auxilium Pharmaceuticals Is Down 3.7% Since Reporting Quarterly Results 2 Weeks Ago (AUXL)
Comtex SmarTrend(R) - Mon Mar 17, 7:03AM CDT
Two weeks ago on February 28th, 2014 Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings and analysts, on average, expected earnings of $0.21 on sales of $112.0 million. Auxilium Pharmaceuticals actually reported earnings of $0.27 per share on sales of $125.9 million, beating EPS estimates by $0.06 and beating revenue estimates by $13.9 million. Since the company's report, shares of Auxilium Pharmaceuticals have fallen from $30.75 to $29.61, representing a loss of 3.7% in the past 17 days.
Auxilium Pharmaceuticals Has Returned 41.4% Since SmarTrend Recommendation (AUXL)
Comtex SmarTrend(R) - Thu Mar 13, 4:48PM CDT
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on December 6th, 2013 at $20.67. In approximately 3 months, Auxilium Pharmaceuticals has returned 41.35% as of today's recent price of $29.21.
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Update on Endo's Product Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 11:00AM CDT
The approval of Aveed has boosted Endo's top line.
Auxilium Pharmaceuticals Earnings Hindsight: Down 2.0% in Last 10 Days (AUXL)
Comtex SmarTrend(R) - Mon Mar 10, 7:42AM CDT
When Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings a week ago on February 28th, 2014, analysts, on average, expected the company to report earnings of $0.21 on sales of $112.0 million. Auxilium Pharmaceuticals actually reported earnings of $0.27 per share on sales of $125.9 million, beating EPS estimates by $0.06 and beating revenue estimates by $13.9 million. Since the company's report, shares of Auxilium Pharmaceuticals have fallen from $30.75 to $30.14, representing a loss of 2.0% in the past 10 days.
Setback for Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 2:55PM CST
Roche recently suffered a setback when it announced that an independent data monitoring committee has recommended that its phase III study, METLung, on onartuzumab (MetMab) should be stopped.
QLT Narrows Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 9:00AM CST
The narrower loss was due to the lower costs incurred by QLT in the final quarter of 2013.
Can Auxilium Pharma (AUXL) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:30AM CST
Auxilium Pharma has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy.
